Protocol Ledger

NCT05840211 · Phase III · ACTIVE NOT RECRUITING

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received En

Interventional Phase III clinical trial protocol NCT05840211 sponsored by Gilead Sciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-05-08 Enrollment: 654 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05840211
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)654 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05840211
Protocol FieldVerified Registry Value
NCT IdentifierNCT05840211
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment654 participants (ESTIMATED)
Registered Start Date2023-05-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI